Welcome to our dedicated page for Eastman Chem Co SEC filings (Ticker: EMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eastman Chemical Company (EMN) SEC filings page provides access to the company’s regulatory disclosures as a public issuer on the New York Stock Exchange. As a global specialty materials company in the plastics material and resin manufacturing industry, Eastman files periodic and current reports that describe its financial condition, results of operations, governance matters, and material events.
Among the most closely watched documents are annual reports on Form 10-K and quarterly reports on Form 10-Q, which include segment information, discussions of end-market demand in areas such as transportation, building and construction, and consumables, and commentary on topics like cash generation, cost structure, and specialty materials performance. Current reports on Form 8-K provide timely updates on specific events, including quarterly earnings releases, Board and executive changes, and other matters the company deems material.
Investors can also review proxy statements for information on Board composition, committee assignments, and director compensation, as well as filings related to executive compensation and governance. For those monitoring insider activity, Forms 3, 4, and 5 disclose transactions by directors and officers in Eastman’s common stock.
On this page, AI-powered tools summarize lengthy filings, highlight key sections, and help explain complex topics such as non-GAAP measures like adjusted EBIT and adjusted earnings per diluted share that Eastman discusses in its earnings materials. Real-time updates from the SEC’s EDGAR system ensure that new EMN filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are available quickly, allowing users to review the underlying disclosures and the AI-generated insights side by side.
Eastman Chemical Co — Schedule 13G/A (Amendment No. 17)
The Vanguard Group reports no beneficial ownership of Eastman Chemical Co. common stock, listing 0 shares and 0% of the class. The filing explains that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report separately in reliance on SEC Release No. 34-39538.
Eastman Chemical Company is asking stockholders to vote at its virtual 2026 Annual Meeting on May 7, 2026. Proposals include electing eleven directors for one-year terms, ratifying PricewaterhouseCoopers LLP as auditor for 2026, an advisory "Say on Pay" vote on executive compensation, approval of the 2026 Omnibus Stock Compensation Plan, and an advisory vote on a stockholder proposal to lower the threshold for calling special meetings to 10%, which the Board opposes.
Eastman highlights its innovation-driven, sustainability-focused growth strategy and reports 2025 results of $8.8 billion in sales, $930 million adjusted EBIT, $474 million net earnings, diluted EPS of $4.10, and adjusted diluted EPS of $5.42. The company generated $970 million in net cash from operating activities and returned approximately $500 million to stockholders through dividends and share repurchases.
The Board emphasizes succession planning, board refreshment, and governance. Ten of eleven nominees are independent, average tenure is 9.7 years, and the Board recorded 99% average attendance at 34 Board and Committee meetings in 2025. Independent committees oversee audit, compensation, governance, finance, and environmental, safety, and sustainability matters, with strong focus on risk management, human capital, and long-term sustainability initiatives.
Holt Adrian James reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical senior vice president and chief human resources officer Adrian James Holt received new equity awards. On February 24, 2026, he was granted 32,116 employee stock options and 4,419 restricted stock units at a grant price of $0.00 per unit as compensation.
One-third of the options become exercisable on February 24, 2027, February 24, 2028, and February 24, 2029. Each restricted stock unit represents the right to receive one share of common stock and will vest and pay out in unrestricted shares on February 24, 2029, subject to continued employment.
Eastman Chemical’s Controller & CAO, Michelle Renee Stewart, reported equity awards consisting of stock options and restricted stock units. She was granted 11,075 employee stock options at an exercise price of $0.00 per option and 1,524 restricted stock units, all held as direct ownership.
According to the award terms, one-third of the options become exercisable on each of February 24, 2027, February 24, 2028, and February 24, 2029. Each restricted stock unit represents a contingent right to receive one share of Eastman Chemical common stock. The restricted stock units will vest and pay out in unrestricted shares on the third anniversary of the grant date, February 24, 2029, subject to continued employment.
McAlindon Julie A. reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical senior vice president Julie A. McAlindon received new equity awards on February 24, 2026. She was granted 24,364 employee stock options, which become exercisable in three equal parts on February 24, 2027, February 24, 2028, and February 24, 2029.
She was also awarded 3,352 restricted stock units, with each unit representing the right to receive one share of common stock. These units will vest and pay out in unrestricted shares on February 24, 2029, subject to her continued employment.
Eastman Chemical CEO Mark J. Costa reported equity awards, not open-market trades. He received an employee stock option grant covering 232,559 shares at an exercise price of $0.00 per option. One-third of these options becomes exercisable on February 24, 2027, 2028, and 2029, respectively.
Costa was also granted 31,993 restricted stock units, each representing a contingent right to one share of Eastman Chemical common stock. These restricted stock units are scheduled to vest and pay out in unrestricted shares on February 24, 2029, subject to continued employment.
Eastman Chemical Company executive Brian Travis Smith received new equity awards. On February 24, 2026, he was granted 53,157 employee stock options with an exercise price of $0.0000 per option. One-third of these options become exercisable on February 24, 2027, February 24, 2028, and February 24, 2029, respectively.
He was also granted 7,313 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Eastman Chemical common stock, and these units will vest and pay out in unrestricted shares on the third anniversary of the grant date, February 24, 2029, subject to continued employment.
Caveness Michelle H reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Company senior vice president and Chief Manufacturing Officer Michelle H. Caveness reported equity awards granted on February 24, 2026. She received 33,223 employee stock options with one-third becoming exercisable on February 24 of 2027, 2028, and 2029.
She was also granted 4,571 restricted stock units, each representing the right to receive one share of common stock. These RSUs will vest and pay out in unrestricted shares on February 24, 2029, subject to continued employment.
Gbadegesin Bosede Ikeolu reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Company senior vice president, chief legal officer and corporate secretary Bosede Ikeolu Gbadegesin received equity awards as part of compensation. She was granted employee stock options for 33,223 shares on February 24, 2026, with one‑third becoming exercisable on February 24 of 2027, 2028 and 2029.
She also received 4,571 restricted stock units on the same date. Each unit represents the right to receive one share of common stock, and these RSUs vest and pay out in unrestricted shares on February 24, 2029, subject to continued employment.